InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,728.27
(
-0.26%
)
Post# of 251715
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

TwoNE1

Send PM Follow Ignore
Followers 1
Posts 129
Boards Moderated 0
Alias Born 01/27/2011

TwoNE1

Re: Biowatch post# 244616

Wednesday, 11/30/2022 6:05:37 AM

Wednesday, November 30, 2022 6:05:37 AM

Post# of 251715
re: Epipen: $AQST epinephrine sublingual film

Aquestive Therapeutics Announces Positive EPIPHAST II Trial Data for AQST-109 When Compared to EpiPen

AQST-109 median time to maximum concentration (Tmax) of 12 minutes was faster than EpiPen® Tmax of 22.5 minutes

AQST-109 repeat dosing provided significantly higher drug plasma concentrations with a Tmax of 8 minutes after administration

Changes in systolic blood pressure and heart rate were similar after a single dose of AQST-109 when compared to a single dose of EpiPen

End-of-Phase 2 meeting with FDA scheduled for fourth quarter 2022 and remaining clinical studies will commence thereafter

Source: https://finance.yahoo.com/news/aquestive-therapeutics-announces-positive-epiphast-110000982.html
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up